imlygic 10e6 injektionslösung
amgen switzerland ag - talimogenum laherparepvecum - injektionslösung - lösung: talimogenum laherparepvecum 1 million u.. - imlygic ist zur behandlung von melanomen mit regionalen oder entfernten metastasen bei erwachsenen indiziert. - transplantat: gentherapieprodukt
imlygic 10e8 injektionslösung
amgen switzerland ag - talimogenum laherparepvecum - injektionslösung - lösung: talimogenum laherparepvecum 100 million u.. - imlygic ist zur behandlung von melanomen mit regionalen oder entfernten metastasen bei erwachsenen indiziert. - transplantat: gentherapieprodukt
venclyxto 10 mg filmtabletten
abbvie ag - venetoclaxum - filmtabletten - venetoclaxum 10 mg, copovidonum k 28, polysorbatum 80, silica colloidalis anhydrica, calcii phosphas, natrii stearylis fumaras corresp. natrium 0.03 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), pro compresso obducto. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika
venclyxto 50 mg filmtabletten
abbvie ag - venetoclaxum - filmtabletten - venetoclaxum 50 mg, copovidonum k 28, polysorbatum 80, silica colloidalis anhydrica, calcii phosphas, natrii stearylis fumaras corresp. natrium 0.15 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika
venclyxto 100 mg filmtabletten
abbvie ag - venetoclaxum - filmtabletten - venetoclaxum 100 mg, copovidonum k 28, polysorbatum 80, silica colloidalis anhydrica, calcii phosphas, natrii stearylis fumaras corresp. natrium 0.31 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), pro compresso obducto. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika
lumykras
amgen europe bv - sotorasib - karzinom, nicht kleinzellige lunge - antineoplastische mittel - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.
imlygic
amgen europe b.v. - talimogen laherparepvec - melanom - antineoplastische mittel - imlygic ist indiziert für die behandlung von erwachsenen mit inoperablen melanom, die regional oder weitläufig metastasierendem (stufe iiib, iiic und ivm1a) ist mit keine knochen, gehirn, lunge oder andere viszerale erkrankung.
kyprolis
amgen europe b.v. - carfilzomib - multiples myelom - antineoplastische mittel - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukämie, lymphozytär, chronisch, b-zell - antineoplastische mittel - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.